Clinical Trial

Autologous Stem Cell Therapy in Patients With Multiple System Atrophy

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study investigates the safety and efficacy of autologous stem cell therapy in patients with Multiple System Atrophy (MSA), a rare and progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia. The trial will evaluate functional outcomes, motor performance, and quality of life compared to placebo/controlled group.
Trial Details
NCT Number NCT07465198
Lead Sponsor Biocells Medical
Conditions MSA - Multiple System Atrophy, MSA
Enrollment 50 participants
Start Date 2026-09-01
Primary Completion 2029-09-01 (estimated)
Study Completion 2031-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-11